Xiangjun Qiu

Prof. Xiangjun Qiu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YZYong-Liang Zhu
Yong-Liang Zhu
SLShuang-Long Li
Shuang-Long Li
CZChun-Yang Zhu
Chun-Yang Zhu
WWWan Wang
Wan Wang
WZWen-Fei Zuo
Wen-Fei Zuo
XQXiangjun Qiu
Xiangjun Qiu

12 March 2025 in Talanta
Verified
Journal Article
Closed access
JFJiaoyuan Fang
Jiaoyuan Fang
YWYun Wang
Yun Wang
YJYihan Jiang
Yihan Jiang
TLTian Li
Tian Li
XQXiangjun Qiu
Xiangjun Qiu

1 May 2016 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
XQXiangjun Qiu
Xiangjun Qiu
JZJian-Long Zhao
Jian-Long Zhao
CHCong Hao
Cong Hao
CYCanli Yuan
Canli Yuan
NTNuan Tian
Nuan Tian
RZRuan-Min Zou
Ruan-Min Zou

1 April 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
CZChen-Jian Zhou
Chen-Jian Zhou
HWHui-Jun Wang
Hui-Jun Wang
CZChun-Yan Zhou
Chun-Yan Zhou
CLChao-Fan Li
Chao-Fan Li
MZMing-Jia Zhu
Ming-Jia Zhu
XQXiangjun Qiu
Xiangjun Qiu
Background: A method for the determination of selinexor by UPLC-MS/MS was established to study the effect of posaconazole on the pharmacokinetics of selinexor in rats. Methods: The experiment rats were divided into group A (0.5% CMC-Na) and group B (posaconazole, 20 mg/kg), 6 rats in each group. 30 minutes after administration of 0.5% CMC-Na or posaconazole, all the rats were given selinexor (8 mg/kg), and plasma samples were collected. The plasma samples underwent acetonitrile protein precipitation, and were separated by UPLC on an Acquity UPLC BEH C18 column with gradient elution. Acetonitrile and 0.1% formic acid were used as the mobile phases. The analyte detection was used a Xevo TQ-S triple quadrupole tandem mass spectrometer and multiple reaction monitoring (MRM) for analyte monitoring. We use acetonitrile for protein precipitation. Results: Selinexor had good linearity (1.0– 1000 ng/mL, r2= 0.996 2), and the accuracy and precision, recovery rate and matrix effects(ME) were also met the FDA approval guidelines. Compared with group A, the Cmax, AUC(0−t) and AUC(0−∞) of selinexor in group B increased by 60.33%, 48.28% and 48.27%, and Tmax increased by 53.92%, CLz/F reduced by 32.08%. Conclusion: This bioanalysis method had been applied to the study of drug interactions in rats. It was found that posaconazole significantly increased the concentration of selinexor in rats. Therefore, when selinexor and posaconazole are combined, we should pay attention to the possible drug–drug interactions to reduce adverse reactions.

1 July 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
YZYong-Liang Zhu
Yong-Liang Zhu
SLShuang-Long Li
Shuang-Long Li
JJJun-Li Jin
Jun-Li Jin
JFJia-Ao Fang
Jia-Ao Fang
XWXiang-Die Wang
Xiang-Die Wang
XQXiangjun Qiu
Xiangjun Qiu

29 November 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LRLan-Hong Ruan
Lan-Hong Ruan
LFLing-Ling Fan
Ling-Ling Fan
KWKun Wang
Kun Wang
WZWan-Qi Zhang
Wan-Qi Zhang
XWXiao-Jun Wang
Xiao-Jun Wang
XQXiangjun Qiu
Xiangjun Qiu
Objective: A robust, quick, and reliable ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for the quantification of erdafitinib in beagle dog plasma was developed and validated to evaluate the changes of posaconazole and isavuconazole on the pharmacokinetics of erdafitinib in beagle dogs, respectively.Methods: This experiment adopted a three-period self-control experimental design. In the first period (group A), erdafitinib was orally administered to six beagle dogs at a dose of 4 mg/kg. In the second period (group B), the same six beagle dogs were orally given posaconazole at a dose of 7 mg/kg, and after 30 min, erdafitinib was orally given. In the third period (group C), isavuconazole at a dose of 7 mg/kg was given orally, and then, erdafitinib was orally given. At the different time points after erdafitinib was given in the three periods, the blood samples were collected. The concentration of erdafitinib was detected by the developed UPLC-MS/MS method. DAS 2.0 was used to calculate the pharmacokinetic parameters of erdafitinib.Results: Erdafitinib had a good linear relationship in the range of 1–500 ng/ml, and the lower limit of quantification was 1 ng/ml. The precision, accuracy, extraction recovery, matrix effect, and stability meet the requirements of the guiding principles. After erdafitinib was combined with posaconazole, the Cmax and AUC0→t of erdafitinib increased by 27.19% and 47.62%, respectively, and the t1/2 was prolonged to 6.33 h. After erdafitinib was combined with isavuconazole, the Cmax and AUC0→t of erdafitinib increased by 23.13% and 54.46%, respectively, and the t1/2 was prolonged to 6.31 h.Conclusion: A robust and reliable UPLC-MS/MS method was fully optimized and developed to detect the plasma concentration of erdafitinib in beagle dogs. Posaconazole and isaconazole could inhibit the metabolism of erdafitinib in beagle dogs and increase the plasma exposure of erdafitinib.